Novo Nordisk: Oral semaglutide lowers HbA1c in adolescents with type 2 diabetes
- PIONEER TEENS phase 3a: first oral GLP-1 RA trial in 10-17-year-olds with type 2 diabetes; randomized, double-blind, placebo-controlled, n=132
- Oral semaglutide (3, 7, 14 mg daily) reduced HbA1c by 0.83% versus placebo at 26 weeks; safety aligned with adult semaglutide trials
- Study duration 52 weeks with primary endpoint at week 26; participants continued metformin, basal insulin, or both
- Novo Nordisk plans regulatory filings for label expansion in the US and EU in H2 and references an Ozempic oral pill launch in the US around Q2 2026
Trial and design
PIONEER TEENS was a 52-week, randomized, double-blind, placebo-controlled phase 3a trial in 132 children and adolescents (ages 10–17) with type 2 diabetes; oral semaglutide was tested at maximum tolerated doses (3 mg, 7 mg, 14 mg once daily) against placebo with participants continuing metformin, basal insulin, or both; the primary endpoint was change in HbA1c at week 26.
Efficacy and safety
Oral semaglutide produced a statistically significant, superior reduction in HbA1c versus placebo of 0.83% at 26 weeks and showed a well-tolerated safety profile consistent with prior semaglutide trials in adults.
Clinical context
Youth-onset type 2 diabetes is rising and linked to higher early-adult mortality risk; global adolescent prevalence was estimated at 14.6 million in 2021 and projected to reach 20.9 million by 2030; current guideline first-line options—metformin and insulin—have limitations (metformin failure in ~50% of adolescents; insulin associated with hypoglycaemia and weight gain), leaving an unmet need for additional therapies.
Regulatory outlook
Pending regulatory approvals, Novo Nordisk plans filings for a label expansion in the US and EU in the second half of the year and is targeting a US launch of an oral Ozempic pill in Q2 2026.
Source: Novo Nordisk